Following its entry into the Australian market via an exclusive tie-up with Epsilon Healthcare, Canadian firm The Valens Company has secured A$540,000 of initial orders for GMP product from local distribution partner Cannvalate.
The orders are for white-labelled cannabis products in various formulations, produced at Epsilon’s Southport facility and sold in Australia and New Zealand.
Epsilon expects to deliver the first two pallets within the coming week, with further deliveries completed early in 2022, primarily for the New Zealand market.
Valens president Jeff Fallows said: “We are excited to report our first GMP production through [Epsilon’s] Southport facility, marking our further expansion into the Australian market.
“The order represents Valens taking advantage of Epsilon’s large-scale GMP manufacturing capability, with the capacity and means to provide further accelerated access to Europe through their TGA and EU GMP capabilities.
“Through Cannvalate’s significant local market presence and leading distribution platform, Valens is well placed with strategic access to a market we see through recent trends being poised for dramatic growth.”
Epsilon CEO Jarrod White added: “This is a significant milestone for the partnership between Epsilon and The Valens Company, as it represents both Valens’ first sale of GMP product in the Australian and New Zealand markets, and Epsilon’s first manufacturing order [under the arrangement].”
“Pleasingly, the receipt of our maiden order has been achieved within a week of announcing our partnership. Epsilon, Valens, and Cannvalate are looking forward to the receipt of more orders as we continue to expand our partnership and explore new markets together.”
